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A ID S  in The Netherlands
C L I N I C A L  A N D  M I C R O B I O L O G I C A L  D AT A ON 36  C A S E S
S.A.  DANNER,  J . M . A .  LANGE,  J . W . M .  VAN DER MEER*,  M . E . I .  SCHI P PER* * ,  J. G O U D S M I T * * * ,  P . J . S . M .  RI ETRA 
J . D .  S P E E L M A N ~ \  P .T .A.  SCHELLEKENS ~ , D. DE HAAS^ a n d  VV. KLUFT&
Summary
On 3 1st December 1984, 36 patients with A ID S  
fulfilling the CDC case finding criteria, had been 
treated in two academic hospitals. A ll  o f  them had 
antibodies to L A V /H T L V -III .  A  description is pre­
sented o f  the clinical features, laboratory data and the 
many microbiological complications. The prognosis 
in patients with opportunistic infections was extremely 
poor; that in patients with only Kaposi's sarcoma was 
considerably better. Neth J Med 1985¡28:487.
Introduction
In the spring of 1981 an unusual clustering of 
Kaposi’s sarcoma and Pneumocystis carinii pneum o­
nia was recognized in previously healthy homosexual 
men in New York City and California12. Soon the 
clinical spectrum broadened, with many different 
so-called opportunistic infections, and in these 
patients evidence of a defect in cellular immune 
responses was found3'8. It was not until February 
1983, over 5 years after onset of disease in the first 
recognized cases, that 1,000 patients with A ID S  
were reported to C D C ', but thereafter there was a 
near doubling of cases every 6 m onths1011.
The highest proportion of cases (73 per cent) was 
seen in homosexual or bisexual men, but soon other 
risk groups were identified: intravenous drug users 
(17 per cent of cases)12, Haitian immigrants to the 
U SA  (3 per cen t)13, haemophiliacs (1 per cent)14, 
receivers of blood transfusions (1 per cent)L\  sexual 
partners of patients or persons at risk (1 per 
cent)111617. A ID S  was also recognized in children 
from parents at risk (64 cases up to December  
1984)1 l lx’22. For the 26 per cent of all cases with a risk 
factor that does not apply to women (i.e. hom osex­
ual males or patients with haemophilia), 76 per cent 
have been males and 24 per cent females (US  
figures)23.
Six months after the first American reports12, the 
first report on European A ID S cases appeared24, 
and today A ID S is recognized in countries all over 
the world2". A large number of cases appear in 
Central Africa (especially Zaire; with 40 per cent 
female patients)2''’2'1, and in Haiti23,25,27,2*. Although it 
is possible that A ID S has been present unrecognized 
for a long time in Central Africa, the recent epidemic 
form is new there, too26,29.
The epidemiology of A ID S soon suggested an 
infectious -  i.e. viral -  aetiology. Extensive evidence  
has now been accumulated that infection with a 
newly discovered retrovirus called lymphadenopa- 
thy-associated virus (L A V ) or human T-cell lympho- 
tropic virus III (HTLV-III), plays a crucial role in the 
pathogenesis of A ID S  and related disorders3"0". The 
LAV/HTLV-III virus shows tropism for the OKT4* 
subset of T-cells and, through a destructive action on 
these cells, brings about the permanent immune 
deficiency resulting in opportunistic infections and 
probably certain cancers38,480607. Antibodies to 
HTLV-III-related antigens can be found in up to 100 
per cent of patients with A ID S 33'37,41’42,51’58. Besides  
A ID S the clinical spectrum of HTLV-III infection 
also encompasses symptom-free individuals, flu-like 
illness, persistent generalized lymphadenopathy, so- 
called AIDS-related complex, and autoimmune dis-
_ 0 0 0 33.35-37.39-44.47-55,58
Total case fatality rate for A ID S  patients in the 
U S A  so far is 47 per cen t11 but, since most cases have 
been diagnosed in the past 2 years, this is certainly an 
underestimation of final mortality. Of patients 
reported more than 3 years ago, 81 per cent have 
died23.
In The Netherlands the first cases were diagnosed  
in i 982yMl4. At the end of 1984, 42 cases meeting  
C D C  criteria'0 had been reported'1'1. In this paper we 
describe the clinical, immunological and microbio­
logical data on 36 of these patients.
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Methods
A ID S was diagnosed in accordance with the CDC  
surveillance definition, which demands two criteria: 
i) the presence of a reliably diagnosed disease at 
least moderately predictive of cellular immunodefi­
ciency; and 2) the absence of an underlying cause of 
the immune deficiency or of any defined cause of 
reduced resistance to the disease*0 .
Included in our study are all patients admitted 
before 3 1st December 1984 either to the Academic  
Medical Centre, University of Amsterdam (30 
patients) or to the Leiden University Hospital (6 
patients), in whom A ID S was diagnosed before 31st 
December 1984. In each case the diagnosis of  
Kaposi's sarcoma was proven histologically. Pneu­
mocystis carinii pneumonia and other infections 
were confirmed by culture results and/or histological 
examinations and/or a diagnostic serological profile, 
except for 3 cases of Toxoplasma gondii encepha­
litis, which were diagnosed on the basis of typical 
CT-scan abnormalities and striking radiological and 
clinical improvement upon anti-toxoplasmosis ther- 
apy.
T-lymphocyte membrane phenotypes of peripher­
al blood lymphocytes were determined by a cyto- 
fluorometric method (Coulter Epics-C) using m ono­
clonal antibodies to mature T-cells (leu-4 or O K T3 ) 
or to helper/inducer (leu-3 or OKT4 ) and suppres­
sor/cytotoxic (leu-2 or O K T 8) T-cell subsets and a 
fluorescein-conjugated goat anti-mouse IgG. Ratios 
of helper/suppressor lymphocytes lower than 0.8 
were scored as depressed.
All material for histopathological studies was 
processed according to a protocol. A postmortem  
was performed in 22 cases. As soon as possible after 
death, mostly within 2 hours, tissue specimens were 
collected from all affected organs for microbiological 
studies. In order to ensure optimal immunohisto- 
logical, electron-microscopic and histopathological 
studies, fragments of tissue from all organs were 
fresh-frozen in liquid nitrogen and fixed in Karnovs- 
ky's fixative and in 4 % buffered formalin respect­
ively. Routinely, 5 u paraffin sections of all organs 
were stained with haematoxylin-eosin, PAS, PAS  
following diastase digestion, Grocott's stain, Ziehl- 
Neelsen stain, and the elastic Van Gieson stain, 
covering all opportunistic infections and malignan­
cies. Biopsy material from living patients (intestinal 
tract, lungs, lymph nodes, etc.) was processed in the 
same way.
Antibodies to HTLV-III were measured using an 
ELISA developed by W .J.A . Krone and others at 
the department of virology, University of Amster­
dam, using a Hy-HTLV-III cell lysateh7.
Results
The mean age of our patients was 39.5 years (range 
23-57 ). All patients were males, all except one being 
homosexual or bisexual men with an active sexual 
life. The one exception was a heterosexual m ono­
gamous man who had received several blood trans­
fusions during heart surgery in the U S A , 4 years 
prior to the first symptoms of A ID S. Thirty-one of  
the patients were of Dutch nationality. The great 
majority reported sexual contacts in the U SA  or with 
persons from the U SA . Four patients had Kaposi’s 
sarcoma only: 24 patients (67 per cent) had oppor­
tunistic infections and 8 (22 per cent) had both 
Kaposi's sarcoma and opportunistic infections. 
Table I lists the prodromal complaints; 32 of  the 36 
patients had one or more complaints; only 3 patients 
with cutaneous Kaposi's sarcoma and one patient 
presenting with acute cryptococcal meningitis 
reported no previous symptoms. Malaise and fatigue 
were almost invariably present, followed by unex­
plained weight loss and unexplained fever. The 
mean interval between onset of symptoms and 
diagnosis of A ID S was 9.7 months (range 0 .5 -36). 
Table II lists the infections or malignancies con­
sidered as evidence of the existence of A ID S. Most 
frequently Pneumocystis carinii pneumonia led to 
diagnosis, followed by Kaposi's sarcoma.
At examination at the time of diagnosis most 
patients had signs of recent weight loss. Weight/ 
height" was low: 19.6 ±  1.6 kg.irf“; 40 per cent had 
fever and 40 per cent were dyspnoeic. Lymphadeno-  
pathy (two or more non-adjacent enlarged lymph 
nodes) was found in 36 per cent, hepatosplenome-  
galy in 25 per cent. Dermatological abnormalities 
were seen frequently: half the patients presented  
with a Candida infection of skin and/or mucous 
membranes, a quarter with Kaposi's sarcoma and 15 
per cent with herpes infection.
TABLE I! PRODROMAL SYMPTOMS IN 36 AIDS PATIENTS
Prodromal symptoms Number o f  
patients
%
Malaise and fatigue 30 83
Weight loss 26 72
Fever 21 5«
Night sweat 17 47
Cough 16 44
Diarrhoea 13 36
Nausea/vomitina 4 11
Neurological or psychiatric
abnormalities 4 11
Lymphadenopathy 14 39
Cutaneous or mucous membrane
abnormalities 14 39
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TABLE li: PRESENTING DISORDERS WHICH HAVE LED TO THE DIAGNOSIS 
OF AIDS IN 36 PATIENTS
Presenting disorder Number oj
patients
Pneumocystis carinii pneumonia 15
Kaposi's sarcoma 10
Oesophagitis caused by Candida albicans 4
Pneumonia caused by Candida albicans 1
Pneumonia caused by cytomegalovirus 1
Encephalitis caused by Toxoplasma gondii 1
Enteritis caused by Isospora belli 1
Enteritis caused by Cryptosporidium spp. 1
Meningitis caused by Crvptococcus neoformans 1
Septicaemia caused by Mycobacterium tuberculosis 1
In table III some laboratory findings are grouped 
together. There was slight leucopenia and marked 
lymphopenia in the peripheral blood: 65 per cent of 
the patients had an absolute lymphocyte count of less 
than 1.0 x  io7l. The absolute number of OKT4- 
positive lymphocytes and the ratio between OKT4- 
positive and O K T 8-positive cells were below normal 
in all patients except one, who presented with a 
solitary Kaposi's sarcoma. He was treated locally, 
but unfortunately he withdrew from follow-up after 
3 months. In-vitro lymphocyte responses to phyto- 
haemagglutinin antilymphocyte serum were dis­
turbed in 34 cases (exceptions were the abovem en­
tioned patient with Kaposi's sarcoma and another 
patient presenting with this disorder). The immuno­
globulin levels were increased. Antibodies to 
HTLV-III were found in 100 per cent of our 
patients.
Infections and malignancies
Fig. 1 lists the opportunistic infections and malig­
nancies diagnosed during life. Two types of malig­
nancies considered part of the A ID S syndrome were
seen: non-Hodgkin lymphoma (maxillary region) in
I case and Kaposi’s sarcoma (cutaneous and/or 
intestinal localizations) in 12 cases. Of the 32 
patients with opportunistic infections, 21 had Pneu­
mocystis carinii pneumonia. In 5 cases there was a 
co-existing lung infection with cytomegalovirus and 
in one case a co-existing infection with Candida 
albicans. Opportunistic bowel infections were 
encountered 7 times, mostly due to Cryptosporidium 
spp. Central nervous system involvement was seen in
II cases. In 7 patients a clinical picture of ‘progres­
sive presenile dementia’ developed with severe 
cerebral atrophy on CT-scan. Ophthalmological 
examination revealed cottonwool spots and/or pre­
sumed CMV retinitis in 4 patients. Chronic perianal 
ulcerative herpes simplex lesions were found in 4 
patients. Disseminated infection with the unusual 
human pathogen Mycobacterium avium intracellu- 
lare was seen in 5 cases, mostly found by culture of 
bone marrow, buffy coat and/or blood.
Apart from the opportunistic infections many 
other infections were seen. In most cases there was 
severe oropharyngeal candidiasis, sometimes relaps­
ing despite treatment. Other infections seen were 
syphilis, Salmonella sepsis, shigellosis, giardiasis and 
amoebiasis, but no distinctive pattern of non- 
opportunistic infections appeared. Fig. 2 shows the 
number of opportunistic and non-opportunistic ser­
ious infections diagnosed during life in the 36 
patients. A mean of two opportunistic infections and 
one non-opportunistic infection was found per 
patient. Only two patients, both presenting with 
Kaposi’s sarcoma, remained free from infections; 
one of them was lost for follow-up after 3 months of  
observation and the other has been observed now for 
9 months. Almost all patients had evidence (serology 
and/or isolates) of past or present E B V , CMV and 
hepatitis B infections. Details about this will be 
reported elsewhere68.
TABLE Hi: SOME LABORATORY FINDINGS IN 36 AIDS PATIENTS AT THE TIME OF DIAGNOSIS
Number Mean Range Normal values (95% 
confidence interval)
Haemoglobin (mmol/1) 34 7-2 4.2 - 10.9 8.1 - 9-9
Leucocytes (x  ioy/l) 35 4.8 2.1 - 12.2 4.0 - 1 1 .0
Lymphocytes ( x  io9/l) 34 0.9 0.2 - 2.9 1.0 - 3-5
Platelets ( x  ioy/l) 34 206 95 - 35« 150 - 350
OKTVpositive cells (x  ioy/l) 32 0.17 0.01 - 0.62 0.5 - 2.0
OKT8-positive cells (x  io9/l) 32 0-54 0.01 - 2.18 0.2 - 1.4
OKT4/OKT8 ratio 33 0.36 0.03 - 1.02 0.8 - 3-2
IgG (g/1) 22 19-3 7.0 - 38.0 8.0 - 19.2
IgM (g/l) 22 3-8 0.8 - 18.3 0.8 - 3.6
IgA (g/l) 22 5-6 0.9 - I7-I 0.7 - 4.1
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Encephalitis by 
Toxoplasma gondii: 3
Encepalitis by 
Papova Virus: 1
Cotton wool spots/retinitis 
by Cytomegalovirus: 4
Non-Hodgkin 
Lymphoma: 1
Pneumonia by 
Pneumocystis carinii: 21
Pneumonia by 
Legionella pneumophila: 1
Pneumonia by 
Candida albicans: 1
Enteritis by ' 
Adenovirus: 1
Intestinal
Kaposi's sarcoma: 6
'Progressive dementia 
by unknown agent: 7
Meningitis by
Cryptococcus neoformans: 1
Oropharyngeal 
Kaposi’s sarcoma: 2
Oesophagitis by 
Candida albicans: 5
Pneumonia by 
Herpes Simplex Virus: 2
Pneumonia by 
Cytomegalovirus: 8
Enteritis by
Cryptosporidium spp.: 5
Enteritis by 
Isospora belli: 1
Cutaneous
Kaposi's sarcoma: 12
Mucocutaneous (perianal) 
Herpes Simplex Virus Infection:
Septicaemia by Candida albicans: 1 
Septicaemia by Cryptococcus neoformans: 1 
Disseminated infection with Mycobact. tuberculosis: 1 
Disseminated infection with Mycobact. avium intracellulare:
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Fig. i. Opportunistic infections and ma­
lignancies in AIDS. I. Findings during 
life since diagnosis in 36 patients.
Fig. 2. Number of opportunistic infections 
and of all infections since diagnosis in 36 
AIDS patients.
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Outcome
The prognosis o f  the disease is poor. So far, 26 of 36 
patients have died. Fig. 3 shows the actuarial survival 
curve. Very remarkably, the patients with only 
Kaposi’s sarcoma are still alive (one of them lost for 
follow-up).
Table IV lists the causes of death in 26 patients. 
Pneumonia was the most important cause of death. 
Although infections with Pneumocystis carinii were 
frequently seen in those patients, that organism was
TABLE iv: CAUSES OF DEATH IN 26 AIDS PATIENTS
Causes o f  death Number o f  
patients
Pneumonia caused by Pneumocystis carinii
and CMV 5
Pneumonia caused by Pneumocystis carinii and
Candida albicans I
Pneumonia caused by Pneumocystis carinii I
Pneumonia caused by bacterial cause 7
‘Progressive dementia’ 2
Intracerebral haemorrhage 2
Progressive multifocal leucoencephalopathy I
Septicaemia caused by Staphylococcus aureus I
Septicaemia caused by Crvptococcus neoformans I
Septicaemia caused by Candida albicans I
Septicaemia caused by Mycobacterium tuberculosis I
Acute cardiac death I
Unnatural death 2
the sole infectious agent responsible for a fatal 
pneumonia in only one case. On the other hand, 5 of 
7 severe lung infections caused by both Pneumocys­
tis and CMV (CM V inclusion bodies seen in lung 
biopsy material and confirmed by culture) led to 
intractable respiratory failure.
Postmortem findings
In 21 of the 26 cases permission for a postmortem  
was obtained. Fig. 4 lists the opportunistic infections 
and malignancies which had not been detected  
during life but were found at postmortem. The 
importance of postmortem examination in A ID S  
cases is clearly illustrated. Numerous episodes of 
fever, wasting or localized symptoms of unknown 
origin, were explained by the postmortem findings. 
Organ involvement by Mycobacterium avium intra- 
cellulare, cytomegalovirus, Cryptococcus neofor- 
mans and Kaposi’s sarcoma was frequently found. 
Besides the clinical syndrome of progressive dem en­
tia due to an unknown agent in 7 patients, two 
additional cases of encephalitis due to an unknown  
agent were found at the postmortem.
Discussion
Shortly after its epidemic appearance in the U S A ,  
the new disease A ID S  reached Europe, emerging
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Encephalitis by 
Cytomegalovirus: 1
Encephalitis by 
Cryptococcus neoformans: 1
Pneumonia by
Cryptococcus neoformans: 2
Pneumonia by 
Mycobact. avium intrac.: 1
Hepatitis/Splenitis by 
Mycobact.avium intrac.: 3
Enteritis by
Mycobact.avium intrac.: 1 
Enteritis by
Cryptosporidium spp.: 1 
Enteritis by
Herpes Simplex Virus: 1
Kidney abscess by 
Candida albicans: 1
Encephalitis by 
unknown agent: 2
Thymic
Kaposi's sarcoma: 1
Pneumonia by 
Pneumocystis carinii: 1
Pneumonia by 
Cytomegalovirus: 7
Respiratory 
Kaposi's sarcoma: 3
Enteritis by 
Cytomegalovirus: 5
Enteritis by 
Candida albicans: 4
Intestinal
Kaposi's sarcoma: 4 
Urogenital
Kaposi’s sarcoma: 2
Lymph node involvement: Kaposi’s sarcoma: 3 
Non-Hodgkin lymphoma: 1 
Cryptococcus neoformans: 3 
Mycobact.avium intrac.: 3
Fig. 4 . Opportunistic infections and ma 
lignancies in AIDS. II. Additional post 
mortem findings in 21 patients.
almost exclusively in urban areas24,2'". This article 
describes the findings in 36 of  the 42 patients 
diagnosed by 31st January 1985 in The Netherlands. 
When compared with the US data, several differ­
ences can be noted: none of  the A ID S  patients was 
an intravenous drug user (17  per cent in the U SA );  so 
far we have found no haemophiliac (1 per cent in the 
U SA ) and seen no female patients (7 per cent in the 
U SA ). All patients except one were homosexual or 
bisexual men with a moderately or highly active 
sexual life.
Two distinct features of the syndrome are the 
multiple simultaneous infections and the poor pro­
gnosis. Many deaths are due to intractable oppor­
tunistic infections, as clearly illustrated in our study 
by the fact that all patients with Kaposi’s sarcoma 
without infections have so far survived. Theoretical­
ly, the poor prognosis might be improved by recon­
stitution of the impaired immune system. No patient 
has so far regained intact immune responses sponta­
neously, nor has any therapeutic regimen succeeded  
in restoring im m unocom petence(iy'71. All that can be 
done at the moment, therefore, is treatment of the 
infections and the malignancies.
Unfortunately, for many of these opportunistic 
infections no effective treatment is known, and for
others therapy gives some clinical improvement, but 
seldom eradication of the micro-organism. Pneum o­
cystis carinii, the most important cause of life- 
threatening pneumonia in A ID S  patients, can be 
treated effectively with trimethoprim-sulphame- 
thoxazole or pentamidine . Our results support 
this: although 21 patients experienced a pneumocys-  
tis infection, only 7 died from this cause. Moreover, 
in 6 of these 7 cases there was a co-existing lung 
infection (CM V in 5 cases, Candida albicans in 1). In 
our experience, supported by the literature7", it is 
mandatory for successful treatment of pneumocystis 
pneumonia to start treatment as soon as possible, 
and especially before respiratory insufficiency 
becomes evident. The extremely high incidence of  
this potentially treatable infection in A ID S patients 
warrants a thorough search in each person at risk. 
Beside physical examination and chest X-ray this 
includes more sensitive techniques such as ,l7Gallium 
lung scintigraphy and determination of a gas diffu­
sion parameter such as CO transfer capacity74'7". If 
the results of all these examinations are normal, the 
likelihood that a patient has a pulmonary infection is 
negligible. If one or more of the results are abnor­
mal, fibre-optic bronchoscopy with broncho-alveo- 
lar lavage and transbronchial biopsy must follow74'82.
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The biopsy and lavage specimens should be pro­
cessed with appropriate stains or cultures for pneu- 
mocystis, mycobacteria, fungi, legionella, and such 
viruses as cytomegalovirus and herpes simplex; in 
addition, the specimens should be submitted to 
routine pathological and cytological analysis'4. 
Using this protocol, we found evidence of pneumo-  
cystis infection in 3 of our patients before there were 
any pulmonary symptoms and signs or chest X-ray 
abnormalities. Unfortunately, adverse reactions to 
co-trimoxazole occur in a large percentage of A ID S  
patients75,s3M and a serious allergic reaction, prompt­
ing discontinuation of this drug, was found in 
one-third of our patients. Toxoplasmosis is another 
infection that can be treated effectively by drug 
therapys\  Life-long therapy is probably neces- 
sarysh,,s7. In our 3 patients with postulated toxoplas­
ma encephalitis, institution of pyrimethamine-sul- 
phadiazine therapy caused prompt disappearance of 
clinical symptoms and CT-scan abnormalities.
A striking neurological syndrome, for which there 
is no treatment at present, is unexplained progres­
sive dementiass. Many A ID S patients eventually 
develop this encephalopathy", and so far it has 
been found in 7 of our patients. In 2 it was considered  
to be the direct cause of death, and in 5 others it 
contributed to death caused by fulminant bacterial 
pneumonia. Symptoms start with apathy, followed  
by progressive mental deterioration. The patient is 
apathetic, bedridden, assumes a foetal position and 
becomes unable to perform the activities of daily 
living. At last diminished consciousness, som no­
lence, and a comatose state develop. Pseudobulbar 
reflexes are found, but no focal neurological symp­
toms. The CT-scan reveals diffuse cerebral atrophy. 
Recently, HTLV-11I virus has been found in brain 
cells of such patients, suggesting that the syndrome is 
the direct result of infection with this virusss.
Common AIDS-related infections which are diffi­
cult to treat include those with the coccidial parasites 
Cryptosporidium spp. and Isospora belli's99<l. Unlike 
the pattern in the immunocompetent, where the 
disease is usually self-limiting^1 3^, they cause severe 
malabsorption and devastating intractable diarrhoea 
in A ID S. In our patient with Isospora belli infection 
we successfully used the veterinary drug amprol- 
ium94. For cryptosporidiosis the therapeutic outlook  
at the moment is bleakS9,9".
For several other opportunistic infections there is 
no specific treatment as yet. Of these, disseminated  
infection with Mycobacterium avium intracellulare 
must be mentioned separately. The organism has 
been isolated from blood and bone marrow in 10-30 
per cent of patients, and has also been identified in
lymph nodes, liver, spleen, soft tissues, lungs, 
sputum and urine9>97. The exact role of this organism 
in producing systemic or localized symptoms or 
pathology is still unclear. So far, no drug or drug 
combination has been documented to be clinically 
effective ' . In-vitro studies usually show resistance to 
conventional antimycobacterial drugs. Excellent in- 
vitro activity against Mycobacterium avium intracel­
lulare isolates has been found with clofazimine, 
ansamycin and amikacin, but clinical results have not 
yet been published*'7. In our series disseminated 
Mycobacterium avium intracellulare was diagnosed  
during life in 5 patients, and in an additional 7 at 
postmortem examination. In one of our patients, 
similar to findings of others9*’99, small bowel lesions 
resembling those of Whipple’s disease, but due to 
Mycobacterium avium intracellulare infection, were 
found. Apart from this case no clearcut disease 
pattern emerged.
Of the viral infections, especially cytomegalovirus 
takes a heavy toll. It causes considerable morbidity 
and mortality, particularly in terms of pneumonia, 
oesophagitis, retinochoroiditis and dissemina­
tion97’100. It may be a cause of adrenal insufficiency in 
A ID S patients1"1"12. It was cultured from the throat 
and urine of nearly all our patients. In our series, 5 of
8 patients with pulmonary CMV involvement devel­
oped fatal respiratory failure. In at least 2 patients 
ocular disorders were ascribed to CMV infection. As  
opposed to herpes simplex and herpes zoster infec­
tions, there is currently no effective therapy for 
disease caused by C M V 1'7.
Although A ID S may be associated with a wide 
range of malignancies (including primary central 
nervous system lymphoma), disseminated Kaposi’s 
sarcoma is by far the most com m on 1"’. Together with 
pneumocystis pneumonia it led to recognition of the 
new syndrome2'4. Although AIDS-related Kaposi’s 
sarcoma is histologically indistinguishable from 
more classic forms, it almost invariably takes a more 
rapidly progressive course, resembling that seen in 
iatrogenically immunosuppressed patients41"31"7. 
Patients present with skin lesions, but at that time 
there is often already co-existing lymph node and 
visceral (especially gastrointestinal tract) involve­
ment4’103106107. Careful examination of the oral cavity 
is mandatory in A ID S patients, since in one out of 3 
with Kaposi's sarcoma involvement of the hard 
palate is found1"’. In one of our patients hard palate 
involvement was the only evidence of Kaposi's 
sarcoma found during life.
In view of the distinctive characteristics of AID S-  
related Kaposi's sarcoma, a new staging classifi­
cation has been proposed1"7. However, the presence
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of B symptoms (weight loss, fever, night sweats) and 
immunological status seem to be more important 
prognostic factors than the more traditional para­
meters of tumour size, employed in this system1"3. In 
agreement with this is that the full natural history of  
AIDS-related Kaposi's sarcoma is not known at the 
moment, since patients sooner or later die from 
opportunistic infections (occult infections presum­
ably being the cause of B symptoms, and opportun­
istic infections being indicative of a worse immuno­
logical status than Kaposi's a lone)1"3. Evidence of 
Kaposi's sarcoma was found in our series in 18 (50 
per cent) patients. This reflects the high prevalence 
of this disorder in homosexual or bisexual men, as 
opposed to other risk groups2'.
Several treatment regimens have been tried in 
AIDS-related Kaposi's sarcoma. The most exten­
sively evaluated single agent cytotoxic drugs have 
been vinblastine and the podophyllotoxin V P -16. 
For the former drug the reported complete response 
rate is 5 per cent (complete and partial response rate 
37 per cent); for V P -16 it is 38 per cent (complete and 
partial response rate 79 per cent)1"3,1"*'11". Total 
response rates of about 40 per cent have been found 
with recombinant alpha interferon1"311"'112. There is 
no agreement on optimal interferon dosage vet, high 
dosage often being limited by intolerable subjective 
symptoms (malaise, fever, headaches)1"3'11"'112. C om ­
bination chemotherapy with doxorubicin, bleomycin 
and vinblastine (D B V ) has been abandoned in view 
of a high rate of opportunistic infections (50 per cent) 
and the possibility o f  aggravating immune suppres­
s ion1"3,11". At New York University Medical Center a 
trial with concurrent therapy with V P - 16 and recom­
binant alpha-2 interferon is now in progress, but 
results have not yet been reported11'. At our centre 
we use a modified, similar protocol. So far, 3 patients 
have been treated with V P - 16 alone, with one partial 
response and 2 not responding. The responder 
stopped therapy after 3 courses because of side 
effects (malaise, alopecia), and Kaposi's sarcoma 
soon became progressive again. Half a year later he 
died from an opportunistic infection. Another  
patient was treated concurrently with V P -16 and 
recombinant alpha-2 interferon and showed a partial 
response. He, too, died from an opportunistic 
infection. The patient with the single presenting 
lesion who was lost for follow-up, was treated locally 
(excision and postoperative radiotherapy).
A ID S is the most dramatic expression of infection 
with a newly discovered retrovirus, called LAV/  
HTLV-III3"05. At present it is estimated that about 7 
per cent of those infected by the virus will develop  
A ID S 44 but, considering the long incubation period.
this may be an underestimation. The disease poses a 
serious threat to persons at risk and has already been 
the cause of  immense human suffering. Our efforts 
should focus on providing appropriate care and 
finding effective therapies (anti-HTLV-III drugs, 
immunomodulation?) for those affected, and on 
protection (screening of  blood donors, development  
of a vaccine) of those at risk, but not yet infected.
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